Mohamed’s study, focusing on pneumonia patients, revealed a significant reduction in CRP and hospital stay with atorvastatin-antibiotic co-therapy, a finding confirmed by a large-scale study conducted by Mortensen et al. [30, 58]. The gene discussed is CRP; the disease is susceptibility to pneumonia measurement.